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Résumé
La déficience en thiarnine entraîne la mort sélective de cellules neuronales dans les
structures thalamiques.
Des études antérieures mettent en évidence le rôle du monoxyde d’azote dans la
pathogenèse de la mort cellulaire causée par cette déficience vitaminique. Dans le but
d’éclaircir l’origine de l’augmentation du monoxyde d’azote (NO), nous avons mesuré
l’expression des isoformes de l’oxyde nitrique synthétase endothéliale (eNOS), inductible
(iNOS) et neuronale (nNOS) dans le thalamus médian, le colliculus inférieur et le cortex
frontal (une région cérébrale non-atteinte) chez les rats où la déficience en thiamine fut
induite par un régime déficient en thiamine et aussi par l’administration quotidienne de
pyrithiamine, un antagoniste central de la thiamine.
Nous avons observé une augmentation significative des niveaux de l’ARN messager
et de l’expression protéique de l’isoforme endothéliale (eNOS) proportionnelle à la sévérité
de la dégénérescence neurologique et de la perte neuronale dans le thalamus médian et le
colliculus inférieur.
Aucun changement dans l’expression des autres isoformes du NOS n’a été observé.
Ces résultats suggèrent que l’endothélium vasculaire est un site important de production de
NO dans les dans le cas de le cerveau des rats déficients en thiamine et que celui-ci pourrait
être la cause des dommages aux structures vulnérables dans cette pathologie.
Mots-clés: Déficience en thiamine, Oxyde nitrique (NO), Endothélium vasculaire, Oxyde
nitrique synthétase (NOS), Oxide nitrique synthétase endothéliale (eNOS), Oxide nitrique
synthétase inductible (iNO$), Oxide nitrique synthétase neuronale (nNOS), Thalamus
médian, Colliculus inférieur, Léon oxydative, Encéphalopatie de Wernicke (EW),
Système nerveux central (SNC).
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Abstract
Thiarnine deficiency is a cause of selective neuronal ceil death in thalamic
structures. Previous studies provide evidence for a role for nitric oxide (NO) in the
pathogenesis of ceil death due to thiamine deficiency. In order to ascertain the origin of the
increased NO in the thiarnine deficient brain, expression of the nitric oxide synthase
isoforms endothelial (eNOS), inducible (iNOS) and neuronal (nNO$) was measured in the
media! thalamus and the inferior colliculus, and compared to the expression in the frontal
cortex (a spared region in this particular pathology) of rats in which thiamine deficiency
was induced by feeding of a thiarnine-depleted diet and the daily administration of
pyrithiarnine, a central thiamine antagonist.
Endothelial NOS rnRNA and protein expression were significantly increased as a
function of the severity of neurological impainnent and degree of neuronal ce!! loss in the
medial thalamus and inferior colliculus. No significant alterations in the expression of other
NOS isoforms were observed. These findings suggest that the vascular endothelium is a
major site of NO production in the brain in thiamine deficiency and that eNOS—derived NO
may account for the selective injury to histologically targeted regions in this disorder.
Keywords : Thiamine Deficiency, Nitric Oxide (NO), Vascular endothelium, Nitric oxide
synthase (NOS), Endothelial nitric oxide synthase (eNOS), Inducible nitric oxide synthase
(iNOS), Neuronal nitric oxide synthase (nNOS), Medial Thalamus, Inferior Colliculus,
Oxidative damage, Wernicke Encephalopathy (WE), Central nervous system (CNS).
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Introduction
1-Sommaire
L’Encéphalopathie de Wernicke (EW) est une atteinte neurologique sérieuse causée
par la déficience en thiamine (vitamine Bi) et est sotivent associée à un état général de
malnutrition. Dans le monde occidental, on retrouve principalement cette pathologie chez
les patients souffrant d’alcoolisme chronique, de vomissements associés à la grossesse
sévères, d’autant que par les anorexiques et les sidéens. D’autre part, la consommation
abusive d’alcool entraîne également des changements rendant ainsi les patients plus
susceptibles à cette pathologie.
L’EW a été initialement décrite en 1881 chez trois patients souffrant d’ataxie, de
nystagmus vertical et de changement cognitifs. Depuis lors, plusieurs chercheurs ont tenté
de déterminer l’étiologie de cette pathologie. Il est maintenant établi qu’une insuffisance en
thiamine est la cause principale de l’EW. Cependant, les mécanismes physiopathologiques
menant à l’apparition de lésions histologiques dans certaines régions spécifiques du cerveau
demeurent jusqu’à maintenant inconnus.
La déficience en thiamine induite par la pyrithiamine (DTP) chez le rat est un
modèle qui émule I’EW en entraînant la dégénérescence sélective de certaines structures
cérébrales. Chez le rat, la DTP évolue progressivement et récapitule les symptômes
neurologiques et la neuropathologie de l’EW, soit l’apparition de lésions focales
symétriquement distribuées (Troncoso et al., i98i).
La pyrithiamine est un analogue central de la thiamine qui franchit la barrière
hémato-encéphalique et entraîne chez l’animal des symptômes neurologiques sévères
(ataxie, opisthonus, nystagmus, perte du réflexe de redressement, convulsions et finalement
le coma). La pyrithiarnine s’accumule dans les structures cérébrales (Rindi et Perri, 1961;
Rindi et al., 1963) et entraîne une diminution rapide des taux de thiamine cérébrale en
inhibant la thiamine pyrophosphokinase (Gubler, 1968; Johnson et Gubler, 1968), l’enzyme
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responsable de la conversion de la thiarnine en ester diphosphate. De plus, la pyrithiarnine
inhibe la capture de la thiarnine dans les tranches de cerveau (Nose et al., 1976) et peut
déplacer la thiamine dans des préparations nerveuses (Cooper, 1968).
Le radical libre monoxyde d’azote (NO) possède des effets toxiques sur le système
nerveux central (SNC) (ladecola, 1997). Cette substance cause des dommages oxydatifs en
réagissant avec les anions de superoxyde (O2-) pour former le péroxynitrite (ONOO-), un
puissant anion oxydant qui se est décompose rapidement en radical hydroxyle OH, un
oxydant hautement réactif qui réagit de façon non spécifique (Merriil et Murphy, 1996).
Une insulte oxydative peut mener à la peroxidation des lipides, la décomposition de l’ADN
et à l’inactivation des enzymes piégeuses de radicaux libres. Les producteurs de radicaux
libres dans le SNC sont les mitochondries, la xanthine oxydase, le métabolisme de l’acide
arachidonique et l’oxydation spontanée de molécules telles que les catécholarnines et
l’hémoglobine.
Les anions de superoxyde formés par diverses réactions sont normalement
transformés en peroxyde d’hydrogène (f1202) de façon spontanée ou aussi par les actions de
la superoxyde dismutase (SOD). Une étude par Langlais et al. en 1997, a démontré la
présence de substances oxygénées réactives dans le thalamus des animaux DTP. Jusqu’à
maintenant la source exacte de la production excessive de substances oxygénées réactives
dans la DTP n’était pas claire.
Les cellules endothéliales et les astrocytes sont des producteurs importants de NO
(Murphy et al., 1990; Moncada et al., 1991). Il a été démontré que le NO peut endommager
la BHE (Au et al., 1985). On sait aussi que les radicaux libres peuvent augmenter la
perméabilité des cellules endothéliales (Chan et al., 1991). Il est donc possible que le NO
puisse modifier l’intégrité fonctionnelle de ce type de cellule et ainsi jouer un rôle
important dans la rupture de la BHE chez les animaux DTP (Calingasan et al., 1 995a;
Harata et Iwasaki, 1995).
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Même lorsque l’activité totale de NOS (l’enzyme responsable de la production de
NO), dans le cerveau est réduite dans les animaux traités à la pyrithiamine (Rao et al.,
1996), l’expression de l’isoforme endothéliale est augmentée dans les régions
vulnérablesdu cerveau ainsi que dans les vaisseaux sanguins.
De plus, le traitement de rats au deprenyl, un piégeur de radicaux libres, accroît la
survie neuronale chez les rats DTP (Todd et Butterworth, 1 99$b), ce qui indique que les
substances réactives oxygénées, dont le NO, jouent un rôle critique dans la pathogenèse des
atteintes cérébrales induites par la déficience en thiamine.
Dans une importante étude par Calingasan et al. (2000) le rôle de l’induction de
eNOS par la voie dépendante de 1’ ICAM-i est un facteur critique dans la mort neuronale
causée par les dommages oxydatifs dans les neurones dont le métabolisme est compromis.
General Introduction
1-1 CHEMICAL STRUCTURE 0F THIAMINE , SOURCES AND NEEDS
Thiamine, which is also known as vitamin Bi is a water-soluble vitamin whose
structure contains a pyrimidine ring and a thiazol cycle bonded to a quatemary ammonium
by a methyiene bridge (Figure 1.1)
NH2
CH2
—
CH3 CH2CH2OH
CH1— N+
CH3 CH2CH2OH
N
TIIIAMINE /
HC
N
H3C —
PYRITHIAMINE N
NH2
figure 1.1 Chemical structures of thiamine and pyrithiamine.
14
Thiamine is a vitarnin essential to most mamrnals, since they are incapable of
autonomous synthesis. The main sources of this nutrient are cereal products, vegetables,
meat, fish, nuts and dairy (Robinson, 1966; Thiessen, 1978). The brain itself contains 1
pglg of fresh tissue (Davis and Icke, 1983). Thiamine plays an extremely important role in
glucose rnetaboÏism that takes place in order to fulfihi cellular energetic processes; therefore
the necessary intake to satisfy those needs must be adjusted according to need.
Theoretically, an average daily intake of approximately 1.0 and 1.5 mg per diem
would be sufficient (Dietary Reference Intake or RDI, 2003).
In the brain, thiamine is most ofien encountered as thiamine diphosphate (TDP)
(Spector, 1982; Davis and Icke, 1983) in contrast with the haematological pathway where
the prefelTed form is that of thiarnine monophosphate (TMP). This difference is indicative
of the probability that thiamine transport in the central nervous system (CNS) is dependent
on a phosphorylation step (Barchi and Braun, 1972; Nose and al, 1974; Spector, 1976).
The existence of a specific membrane phosphatase that is favorable to transport would
explain the reason why certain regions of the brain would be less vuinerable to the
depletion ofthiamine stores than others.
1.2 ROLE 0F THIAMINE IN THE CNS
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Thiarnine plays its most significant role in thc CNS as an enzyme cofactor. There are
three thiarnine-dependant enzymes in the CN$: Pyruvate Dehydrogenase Complex
(PDHC), Œ-Ketoglutarate Dehydrogenase (aKGDH) and Transketolase (TK).These three
enzymes are critical factors in glucose metabolism.
1.3 CLINICAL IMPLICATIONS 0F THIAMINE DEFICIENCY.
1.3.1 Wernicke —Korsakoff Syndrome
Wernicke encephalopathy part of the Wernicke-Korsakoff syndrome, is a
neurological disorder whose aetiology is generalized thiamine deficiency, usually the
product of poor nutritional status. In economically deveÏoped countries, the highest
incidence is found amongst the chronic alcoholic patient population. Aïcohol abuse in itself
leads to dysfunction of thiamine absorption making these sarne individuals even more
vulnerable to this vitamin deficiency.
While experimenting by feeding pigeons with a thiamine-free diet, Sir Rudolph
Peters (Kinnersley and Peters, 1930) successftilly dernonstrated the accumulation of
pyruvate and lactate at the brainstem that preceeded the appearance of neurological
symptoms. This discovery was the first to suggest the existence of a « biochemical lesion ».
Later on, Bowman et al. (1939) described the therapeutic effect of thiamine
administration in the treatment of a patient suffering from cognitive changes (which are one
ofthe symptoms encountered in this pathology). Thiamine was used successfully to reverse
the ophthalmological as well as cognitive symptoms by Joliffe et al. in 1941.
On the other hand, the residual psychosis, also known as Korsakoff psychosis,
seems to be refractory to this treatment modality. Thus, treatment of Wernicke
encephalopathy with thiamine has been standard for several decades but the
pathophysiology ofthis disorder has flot been entirely explored.
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1.3.1.1 Clinical presentation
This syndrome can be described as having an acute stage, that of Wernicke
encephalopathy which is sensitive to treatment with thiamine and the more chronic stage,
that of Korsakoff psychosis which seems refractory to this treatment rnodality. Both stages
are respectively the neurological and psychiatrie facets of a same syndrome which can be
found amongst affected patients.
Three types of symptoms such as cognitive deficits, ataxia and also the
ophthalmological type of symptoms such as ophthaimoplegia or vertical nystagmus
characterize Wernicke encephalopathy (EW). Ail of these symptoms are seldom found in
conjunction, but combinations of some of them and most frequently, ataxia and
ophthalmological manifestations are the most common clinical profile presented in
practice.
The characteristic cognitive alterations seen in this syndrome is inclusive of a
significant level of apathy, difficulty concentrating on a particular task or thought as well as
amnesia and perceptional alterations. In a few cases, the reversai of these behavioural and
cognitive symptoms is achieved upon therapeutic thiamine administration. In rnost patients,
improvement of the symptoms is progressive and sometimes is replaced by learning
disabilities and (short-term) memory abnormalities. Memory integrity is rarely recovered.
Ataxia which is an important symptom for an accurate diagnosis is harder to
confirm clinically, since it can vary from a subtie motor coordination problem to a severe
handicap and it is only after performing a specific neuroiogical examination, that the
diagnosis can be rendered. Thiamine is oniy marginally successflul as a treatment for this
symptom.
Ophthalmologic manifestations are important landmarks and can therefore assist in
rendering differential diagnosis. These include nystagmus (85%), paresthesis of lateral
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abductors (54%) and paresthesis of coordinated vision (44%). Ophthalmological symptoms
are rapidly alleviated afier therapeutic thiamine administration.
Korsakoff psychosis is a very unique and characteristic set of symptoms in this
disease process and it presents with short-term memory problems and learning deficiencies.
Approximately 20% of patients recover completely from these symptoms and an additional
20% of them is non-responsive to treatment, with most of the patients falling in between
these extremes.
1.3.1.2 Neuropathology
In an important series of studies, Victor et al. (1989) showed afier the post-mortem
evaluation of the brains of WE patients, macroscopic histopathological changes that are
inclusive of an increase in size of the third and lateral ventricles and the thalamic
subventricular regions, which are affected by lesions. On the other hand, cerebral atrophy is
found in 20% ofthe patients and most often seen in the frontal lobes (Harper, 1983).
Rapid and accurate diagnosis of the disease is effective not only towards promptly
improving the neuropathological abnormalities. The selectively vuinerable regions do not
have a common embryological source (Hamilton et al., 1952) and do not share
vascularisation.
The earliest histological changes in thiamine deficiency are morphological
alterations in glia (Collins, 1967; Robertson et al., 1968). Macroscopic atrophy of the
mamillary bodies can be seen when the dissection of a fixed brain is performed. This lesion
is symmetrical with pinpoint hemorrhages in some cases.
Lesions found in the gray matter are similar and can be observed around the
aqueduct, inferior and superior colliculus and the inferior portion of the IVth ventricle. The
cerebellar vermis is mainly targeted at the folia, anterosuperior to the prirnary fissure. In
cases of both Korsakoff psychosis and WE the lesion distribution is similar, with the
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exception that in the latter the additional implication of lesions in the medial thalamus and
hypothalamus has been found. Other targeted regions are the thalamus; hypothalamus,
rnidbrain, inferior olive, cerebellar vermis and the vestibular lateral nuclei (Torvik, 1985;
Mair et al.1979; Victor, 1976) as well as the basal nucleus ofMeynert (Arendt et al., 1983).
An interesting particularity of this pathology is that although the periventricular
regions are the most affected by lesions, most of its neighboring structures are spared. This
is a good example of the regional specificity of the lesions occuning in this nutritional
disorder. At histological observation it is important to discern that the damage seen in the
rnammillary bodies and sub-ependymal area is principally caused by chronic degeneration
of neuropil, which develops spongiosis, and loss of myelinated fibers. These types of
lesions are due to severe endothelial inflammation but in this case, neurons are not
especially targeted (Torvik, 1985; Victor, 1976).
Contrary to this, in the thalamus and inferior olive, the exact opposite type of
lesions are found, so that neurons are particularly damaged, and relatively sparing the
neuropil (Torvik, 1985; Victor, 1976). Torvik’s 1985 study suggested the presence of two
different types of lesions and indicates the possibility that cellular brain injury rnight be the
product of several mechanisms.
Lesions to the cerebellar hemisphere and to the anterior vermis are characterized by
the decrease in Purkinje celis and the augmentation in Bergman astrocytes that in more
severe cases are accompanied by an important neuronal loss in the granular layer.
1.3.1.3 Thiamine status and alcoholism
In economically developed countries, the most frequent cause of thiamine
deficiency is chronic alcohol abuse. This is caused by the generally poor nutritional status
seen in these individuals and the insufficient thiamine consumed in their diets (Leevy et al.,
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1965; Neville et al., 1968). To add to this insuit, excessive alcohol consumption alters
normal thiamine phosphorylation.
It has been shown in both humans, (Tomasulo et al., 1968; Thomson et aI., 1970) as
well as in a rat model (Hoyumpa et al.. 1978), that ethanol reduces intestinal absorption of
this substance. It was shown that following oral administration of 2Omg of thiamine,
maximal absorption is of 4.77±0.36mg in normal patients but on the other hand, the
absorption is decreased to 1 .50±0.3mg in alcoholic patients.
The mechanism proposed to explain this phenomenon was the inhibition of active
transport (Hoyumpa et al., 1975) through suppression of NaKATPase in the enterocytic
basolateral membranes (Hoyumpa et al., 1977).
Intestinal concentration seems to be a determining factor for inefficient absorption
more so than the length of time of the exposure of the enteric tissues (Hoyumpa et al.,
1978). Another aggravating factor is the common co-deficiency in alcoholics of vitarnins
36 and 312. This leads to a reduction in thiamine absorption (Thomson et al., 1972; Howard
et al., 1974; Nishino and Itokawa, 1977). Adding folates to the diet improves this effect
(Davis and Srnith, 1974).
Alcohol abuse also reduces the stores and capture of thiamine in the liver and also
increases the depletion ofthis substance (Heaton, 1977; Howard et al., 1974; Chi-Po Chen,
1978). The consequence is that in the alcoholic patient the depletion ofthe hepatic thiamine
stock is more rapid and its replacement mechanism is less efficient.
Alcohol abuse slows down TPKase activity which catalyses the synthesis of TDP, the
active form of thiamine when it is utilized as a cofactor (Davis et Icke, 1983; Leevy and
Baker, 1968). This downregulation of the conversion rate could explain why WK patients
are less responsive to thiamine treatrnent.
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1.4 EXPERIMENTAL WERNICKE ENCEPHALOPATHY
1.4.1 Treatment with Pyrithiamine (PTD)
Pyrithiamine-induced thiamine deficiency or PTD, is a recognized
experimental model that is used to reproduce and study the pathophysiological
changes of the human version of this disease, which is Wernicke encephalopathy,
because the biochemical changes and selective histological lesions seen in the
human disease are closely mirrored in this animal model (Troncoso et al., 1981).
Experimental thiamine deficiency in rodents is an excellent means to study
the different mechanisms through which a general and chronic dysfunction of
oxidative metabolisrn can lead to selective neuronal loss. The targeted brain regions
usually start showing alterations after 10 consecutive days of treatment, narnely
symmetricai lesions in the thalamus, mammillary bodies, the pons and the gray
matter in the periaqueductal area. The cerebellum, cortex, and striatum are mostly
spared. Lesions are characterized by severe inflammation and hemorrhagic necrosis
that affects astrocytes, myelinated layer and dendrites. At the symptomatic stage
(afier the loss ofthe righting reflex), these lesions become more extensive and reach
the thalamus, hippocampus, the inferior colliculus, the lateral vestibulary nuclei, the
inferior olive, and the globus pallidus (Troncoso et al., 1981; Irle and Markowitsch,
1983).
Neuropathologically, the first change in the vulnerable regions is the
disruption ofthe blood-brain barrier (BBB) (Calingasan et al., 1998). Ccli death and
increased immunoreactivity accumulation to B amyloid precursor protein (APP) in
perikaya and abnormal neurites around the lesions follow this (Calingasan et al.,
1995). Mechanisms responsible for the region specific BBB disruption, the cellular
loss, and the altered expression of APP in the thiamine deficient rat are so far not
ftilly understood. A favored hypothesis is the one that proposes that certain
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substances released by endothelial celis and microglia such as nitric oxide (NO) or
other producers of free radicals are the likely sources of damage. Relatively
recently, an increase in the production of free radical species was shown in thiarnine
deficiency (Langlais et al., 1997).
NOS (the subject of this study) plays an important role in CNS physiology
but in some cases, it is also a powerftil mediator for neurotoxicity in several of the
pathologies that affect the central nervous system. Several prior studies in other
neuropathologies, have proposed that the excessive production of NO can be related
or even be the cause of the increased permeability of the BBB (Mulligan et al.,
1991; Corbet et al., 1992; Boje, 1996). Microglia are involved in the pathogenesis of
neuronal ccli loss in certain neuropathologies sucli as Alzheimer’s (AD) or
Parkinson’s (PD) Diseases (Barron, 1995). It has been demonstrated in in vitro
models, that activated microglia damage neuronal ceils through NO (Chao et al.,
1992).
On the other hand, oxidative stress derived from mitochondrial dysfunction
is also critical in the development of several pathologies including the
aforementioned ones (AD and PD) as welÏ as ischemia, Huntington’s disease (HD)
and amyotrophic lateral sclerosis (ALS) (reviewed by Fiskum et al., 1999). The
majority of these diseases have shown several common mechanisms that contribute
to the neurodegenerative process interestingly and among others, inhibition of a
ketoglutarate dehydrogenase (ŒKGDH) which is a thiamine-dependent enzyme in
the TCA cycle that is affected by several factors (revised by Gibson et al. 2000).
Thiamine deficiency leads to oxidative mitochondrial dysfunction and thus
to neuronal death (Héroux and Butterworth, 1992). Mitochondrial dysftinction can
be reversible afier thiamine cofactor administration (Sparacia et al., 1999).
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This inhibition of ŒKGDH is the eariiest metabolic pathological event seen
(Butterworth et al., 1986, 1989). It leads to alteration in mitochondrial function
which is conducive to a cascade of abnormalities that end in oxidative damage.
In the PTD rats, this damage is inclusive of the factors mentioned earlier
such as heightened BBB permeability, augmentation in free radical production and
increase in the expression of superoxide dismutase (SOD) (Todd and Butterworth,
1997) which is accompanied by increased microglial activity (Todd and
Butterworth, 1999). Other important effects are increased production of NO
(Calingasan et al., 1998) and glutamate excitotoxicity caused by the increase in
extracellular glutamate concentrations and the impaired function of the glutamate
transporters (Hazell et al., 1993, 2001).
1.4.1.2 The PTD Rat Protocol
The animais used in this particular study, were male $prague-Dawley rats
weighting approximately between 200 and 225 g. They were weighed daily and
were given a subcutaneous (sc.) injection of pyrithiamine (0.5mg/kg). Rats in the
control group were pair fed to the ones in the PTD (“symptomatic”) group and fed
the same amount of thiamine deficient food. The control animais also received a
supplemental sc. injection ofthiamine (0.1 mg/kg).
Afier 12 days of continuai treatment, an additional group was designated
amongst the PTD-treated rats and selected for a “pre-symptomatic” group afier
careful observation and evaluation for characteristic symptoms and signs such as
development of rotational movement and tendency towards backwards movement
without the presence of seizures or loss ofthe righting reflex (Hazell et al., 1998a).
The rats in this group were sacrificed at this time.
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Treatment was continued in the rest of the groups, as previously described,
until they displayed ioss of righting reflex, that is, when they were unable to turn
over when placed on their backs. This was considered as the acute symptomatic
stage.
1.4.1.3 Thiamine Levels
Thiamine deficiency is generaiized and systemic. The brain is the last organ
to be affected, which is evidence ofhow this structure is particularly protected.
Neurological damage is only apparent when thiamine serum levels reach
20% of their normal values (Aikawa et ai., 1984). Neurological symptoms are flot
manifested until TDP decreases in the brain (Pincus and Wells, 1972). In order for
the neurological repercussions to appear, thiamine levels must reach approximateiy
20 to 50% of their control value in the brain, (McCandiess and Schenker, 1968;
Pincus and Weiis, 1972; Aikawa et ai., 1984; McCandiess, 1985). Afier
examination of the different regions, the pons and midbrain showed a significant
decline in the TDP levels with regard to the cerebellum and cortex which are
relatively spared (Pincus and Weiis, 1972; Pincus and Grove, 1970). It has aiso been
demonstrated that in asymptomatic animals the TDP level was around 35% of its
control value but in those animais that were symptomatic this value was only of
25%.
In 1973, Murdock and Gubier showed that the use of pyrithiamine was
significantly more effective in producing thiamine deficiency than strictly dietary
deficiency. It has been aiso shown that if neurologicai manifestations become
noticeabie when brain thiamine level attains 20%, these symptoms are easiiy
reversed afier a minimal increase of this nutrient (26%) (McCandless and Shenker,
1968).
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1.4.1.3 Cerebral energy metabolism
Previous studies have shown that cerebral vulnerability is related to the
decrease in adenosine triphosphate (ATP) levels in the regions that are targeted by
histological lesions (Aikawa et al., 1984). Since ŒKGDH is a key rate limiting
enzyme of the ATP-yielding TCA cycle, specific reductions in its activity (Gibson
et al., 1984; Butterworth et al., 1986; Butterworth and Héroux, 1989) are probably
responsible for the decline in the total energy production and by this means of the
decrease in ATP in the sensitive regions of the brain during PTD. This likely is a
significant contributor in determining the survival of celis in particular brain regions
during the course ofthe protocol.
PTD leads to a decline in generalized glucose utilization. A localized rise, then a
decline follows this initial decrease, and this phenomenon is limited to the
histologically targeted regions (Hakim and Pappius, 1983). The alterations in
glucose utilization precede the appearance of the neurological symptoms. As
demonstrated by Aikawa et al. in 1984, the fall in ATP and phosphocreatine (PCr)
levels is probably linked to the final decrease in glucose utilization. Administration
of thiamine afler these developments, is only partiaÏly effective in restoring normal
glucose utilization and it has been shown that this effect is improved if
administration of thiamine takes place prior to the temporary increase stage (Hakim
et al., 1983). These types of studies suggest that the histologically targeted regions
in thiamine deficiency probably develop functional impairments before the acute
symptomatic stage occurs.
1.5 The « Biochemical >Lesion.
As it was stated in the general introduction, three major enzymes depend on
thiamine in the form of TDP for their function. These are PDHC, aKGDH and TK.
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In early studies by Peters (1936 and 1969), thiamine deficit brought about by a diet
based on polished rice, ied to the occurrence of opistonus and accumulation of lactate in
brainstem structures in a pigeon model that occurred prior to the development of the
structural lesions. These metabolic abnormalities which were reversed in vitro gave risc to
the development of the concept of a “biochemical lesion” caused by abnormal pyruvate
oxidation.
In more recent studies, it has been shown that this lesion is the product of a decline
in the activity of brain aKGDH that occurs during PTD treatment in rats (Gibson et al.,
1924; Butterworth et al., 1986). Also, the fail in the activity of aKGDH in the symptomatic
PTD rat brain has been associated with an increase in alanine (Gibson et al., 1984;
Butterworth and Héroux, 1989) and lactate (McCandless, 1922; Hakim, 1984; Munujos et
al., 1993), supporting the hypothesis that suggests that there is a decrease in pyruvate
entering the tricarboxylic cycle flux (TCA). ŒKGDH activity is severely restricted in most
regions that eventually develop histological lesions in PTD animais (Gibson et al., 1984;
Butterworth et al., 1986; Butterworth and Héroux, 1989) particularly, in the medial
thalamus.
The reduction in total aKGDH activity is thought to be the cause for the reversible
reduction in the concentrations ofneuroactive aminoacids such as: glutamate, aspartate, and
GABA, which demonstrates the importance that the activity of these amino acids may have
on the formation of this biochemical lesion. Despite this, normalization of ŒKGDH, GABA
and aspartate activities afier thiamine replenishment is only partial which might be a sign of
the permanent structural damage that takes place in this neuroanatomical region.
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1.3 Schematic diagram ofthe glycolytic and TCA pathways. Thiamine dependent enzymes
are indicated with an asterisk. (Adapted from Hazeli et al., 1 99$a).
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Although the changes in pyruvate and lactate levels would suggest that there could
possibly exist a reduction in PDHC levels, these remain unperturbed during PTD (Gibson
et al., 1984; Butterworth et al., 1985; Elnageh and Gaitonde, 198$).
Btit dramatic and ofien penrianent decreases have been observed in transketolase
(TK) levels in both vuinerable and refractory regions to the characteristic histological
lesions in the brain (McCandless and Shenker, 196$; McCandless et al., 1976; Gibson et
al., 1984; Giguère and Butterworth, 1987) (figure 1.3). Moreover, progression towards the
manifestation of neurological symptoms has been correlated to reduced levels in TK
activity in the brain (Dreyfus, 1962,1967). TK plays a role in the pentose phosphate shunt,
which is a pathway that produces both ribose sugar residues needed for nucleic acid
synthesis, and fatty acids necessary for the adequate sustenance of the membrane
phospholipid integrity.
It was shown in 1996, that destabilization of TK protein or decrease in mRNA
translation of this enzyme produced by thiamine deficiency. is the principal cause for the
decrease in activity (Sheu et al., 1996). On the other hand, despite the reduction in TK
activity, the total activity of the pentose phosphate shunt seems undisturbed in PTD-treated
animals (McCandless et al., 1976). This leads to the notion that this pathway may well be
an important metabolic store. With the evidence accumulated so far on the subject, the
conclusion can be drawn that modifications in PDHC and TK activity levels are probably
not significant factors in the development of the reversible neurological symptoms of PTD.
In contrast to this, a prolonged period of reduced TK activity is likely to lead to insufficient
production of nucleic acids, lack of integrity of the cellular membranes and the ensuing
demyelination that is a characteristic of WE.
In studies made in 1940 by Mann and Quastel on the development of the
neurological symptoms that accompany thiamine deficiency, it was shown that the rate of
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synthesis of acetylcholine was significantly eievated in brain suces of thiamine deficient
pigeons after in vitro addition of thiamine. More recently, it was reported that thiamine
deficiency is a cause for the decline in levels of the precursor for acetylcholine, Acetyl
coenzyme A (Heinrich et al., 1973) in the brain, and logically those of acetylcholine in the
sarne organ (Lissak et al., 1943; Cheney et al., 1969; Heinrich et al., 1973). These findings
were contested since other research teams were flot able to reproduce these resuits and
found no alterations in brain acetylcholine metabolism in the same model (Reynolds and
Blass, 1975,Vorhees et al., 1977). In support of this point of view, the activities of a
cholinergic marker, the enzyme choline acetyltransferase remained stable throughout the
duration of the treatment (Thompson and McGeer, 1985; Amstrong —James et al., 1988)
which means that there is no significant loss of neurons in this model. Furthermore,
administration of eserine, which is an acetylcholinesterase inhibitor, before the onset of
seizures, increases PTD rat survival time (Cheney et al., 1969). Moreover, afier observation
of the effects of cholinergic agents on the ability of thiarnine deficient animais to perform a
string test test in which they cross the length of a string, and also on open fteld staring
behaviour, it has been established that a central muscarinic cholinergic lesion is develops
early in the pathology (Gibson et al., 1982).
Afier gathering the existing evidence, it can be concluded that there are dysfunctions
in the cholinergic system in thiamine deficiency yet these are more likely to be due to
diminished acetylcholine synthesis than to a structural lesion (Gibson et al., 1984).
1.5.1 Effects on thiamine-dependent enzymes during PTD.
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As stated in the previous section, pyrithiamine induced thiamine deficiency has
distinct and specific effects on thiamine-dependent enzymes that play a major role in ce!!
energy metabolism.
Their obvious decrease when there is a general depletion of the cofactor, leads to
decreased efficiency of the TCA cycle and consequently of lipid, acetylcholine, ATP and
associated neurotransmitter synthesis and logically to CNS pathology (Dreyftis and Hauser,
1965; McCandless and $henker, 1968; Hollowach et al., 1968; Butterworth, 19$5b).
1.5.1.1 PDHC (Pyruvate dehydrogenase complex)
PTD treatment produces an increase in the levels of pyruvate and lactate. This is an
effect that is particularly evident in the thalamus and vestibular lateral nuclei and sparing
the cerebellum and cerebral cortex (Ho!Iowach et aI., 1968; Collins and Converse, 1970). In
PTD, there is a decline in pyruvate oxidation (Bennett et al., 1966; Gubler, 1961). A few
studies have found changes in the activity ofthis enzyme in the brain.
In 196$, Hollowach et al. observed a 25% decrease in this enzyme and proposed
that this change could be the cause of the neurological alterations that develop in this
pathology. Gibson et al. (1985) only found a significant reduction (32%) in the vuinerable
regions (mammillary bodies) but it remained unchanged in the cortex. In that same year, it
was shown that PDHC activities are selectively downregulated from 15 to 30% in the
rnidbrain and pons (vestibular lateral nuclei). Thiamine administration reversed the
characteristic neurological symptoms and simultaneously diminished the abnormalities in
brain PDHC, but this was only true in the case of purely dietary thiamine deficiency. In the
case of PTD, although the pathology is significantly accelerated, selective regional
modifications in PDHC activity are not present (Butterworth et al., 1985).
1.5.1.2 OEKetoglutarate Dehydrogenase (ŒKGDH)
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PTD treatrnent in the rat has much more serious consequences and more extensive
neurological repercussions than those caused by purely dietary thiamine deficiency. In
PTD, ŒKGDH activities are substantiaily reduced in ail areas ofthe brain with the most
dramatic alterations occurring in the sites most vuinerable to pyrithiamine treatment (lateral
vestibular nuclei, midbrain, hypothalamus, meduila and pons).
In some cases changes in ŒKGDH precede the onset of neuropathoiogicai
symptoms. These reductions in ŒKGDH may explain prior observations of iocalized
seiective changes in energy metabolism and decreases in synthesis of glucose-derived
neurotransrnitters (acetyichoiine, GABA, glutamate) in PTD animais.
Afier thiamine administration to PTD animais, characteristic symptoms are
eiiminated and the activity of aKGDH is restored in the brain. These observations indicate
that the reversible symptoms of WE in humans are likely to be caused by deficient ŒKGDH
function in the vuinerable regions ofthe CNS (Butterworth et al., 1986).
1.5.1.3 Transketolase (TK)
In PTD, total transketoiase (TK) activities are aiways reduced in ail of the
structures observed (McCandless et ai., 1976; Gibson et aI., 1984). The activity of this
enzyme is significantiy reduced before the onset of neurologicai symptoms and the
appearance of the symptoms is mirrored by an even stronger decline of TK.
In this model, transketolase activities are decreased equally in both vuinerable and
refractory regions and these modifications remain unchanged after reversai of the
neurologicai symptoms with therapeutic thiamine treatment (Giguère et al., 1987).
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1.5.1.4 ATP Level
Some studies undertaken in the 1960’s implicate the decrease in ATP levels in the
developrnent of necrotic oedematous lesions that are seen early in the pathogenesis and
suggest that the fali in PDHC activity might be cause of this event (Robertson et al., 1 96$).
On the other hand, a consistent level of ATP has been observed despite the decrease in
PDHC, concluding that PDHC affects the diseases process by other means than those
related to ATP production (McCandless et aI.1968, 1976).
More recently, studies done in the PTD model (Aikawa et al., 1984) have shown
that there are decreases in ATP and phosphocreatine (PCr), an energetically rich phosphate
in the brainstem and the diencephalon and as expected that the cortex and cerebellum are
characteristically spared. These declines become more severe after the onset of neuroÏogicaÏ
symptoms. A few years later, these observations were confirrned but the same types of
lesions were found also in the cerebral cortex (Takahashi et al., 1988).
These abnorrnalities in mitochondrial rnetabolism in thiamine deficiency are a
product of the reduction in the synthesis of the thiamine-dependent enzymes which leads to
a lowered ATP production. This is one possible source of the irreversible neurological
changes in this model and in WE, which was also observed in a study by Parker et al.
(1984).
1.5.1.5 Lactic Acidosis
Lactate accumulation is a weÏl-known feature of thiarnine deficiency (Kinnersley
and Peters, 1930; Holowach et al., 1968, McCandless and Schenker, 1968). The
n
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augmentation in lactate levels and the consequent acidosis this provokes, have been shown
to be lirnited to the regions that later develop characteristic histological damage
(McCandless, 1982; Hakim, 1984; Munujos et al., 1993).
In the rat model this causes changes in pH (acidification) in both in isolated ceils
and tissues (Mutch and Hansen, 1984). This is also an important factor in associated
syndromes such as hypoxic and ischemic cerebral lesions (Myers, 1979; Pulsinelli et al.,
1982; Plum, 1983; Yoshida et al., 1985).
In related pathologies, oedema has been shown, particularly in guai ceils (Myers,
1979; Kalirno et al., 1981; Jenkins et al., 1984; Siesjô, 1985) and oedema can be produced
by acidosis inside and well as in the exterior cellular environment (Collins, 1967;
Robertson et al., 1968; Watanabe and Kanabe, 1978; Watanabe et al., 1981). Lactate
accumulation and the change in pH that take place are probably factors contributing to
neuronal ceH death in both this model and WE (Hakim, 1984).
1.6 MECHANISMS 0F NEURONAL CELL DEATU IN THIAMINE
DEFICIENCY.
1.6.1 NMDA-receptor mediated excitotoxicity
Aherations in glutamate homeostasis are often suggested as being the sources of the
pathology that develops in the CNS in the PTD animal. Glucose levels are decreased in the
totality of the brain (Butterworth, 1982), and also in the characteristically vuinerable
regions such as the thalamus and the pons (Butterworth and Héroux, 1989). These
observations support studies that describe a decrease in the conversion of glucose
radioactively labeled with [‘4C] into glutamate in PTD rats (Gaitonde et al., 1975). Ca2
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dependent glutamate release was also shown to be reduced in hippocampal suces of
symtomatic animals (Lê et al., 1991).
During observations carried out in 1988 by Amstrong-James et al. it was recorded
that progression and general aspect of damage in lesions to the medial thalamus which
present during thiamine deficiency, have a similar appearance to those lesions present when
excitatory arninoacids are administered The ultrastructural aspect of the affected thalamus
is also similar to that observed in necrosis mediated by excitotoxicity (Olney, 1978). To
support this finding, it was shown that it is possible to limit the damage caused by ceil
death in the vuinerable regions in this pathology using MK-80 1 which is a non-competitive
antagonist of the NMDA receptor (Langlais and Mair, 1990; Todd and Butterworth,
1 99$a). furthermore, another supporting factor that points to glutamate excitotoxic
mechanisms is that extracellular glutamate concentrations were found to be augmented in
the posterior thalamus during PTD (Hazeil et al., 1993; Langlais and Zhang, 1993).
Significant neuronal loss bas been observed and it becomes apparent before the onset of
neurological symptoms (Leong et al., 1994; Todd and Butterworth, 1998a; Hazeil et aL,
1 998a).
Increases in the extraceilular glutamate concentration in the vuinerable regions such
as the thalannis in PTD animais can iead to unrestricted entry of Ca2 into the celi. The loss
of calcium homeostasis bas been shown to be an important cause of cdl death through
excitotoxic processes in several of the neurodegenerative pathologies (Olney et al.,
1971; Schanne et al., 1979; farber et al., 1981; Raichie, 1983; Siesji and Bengtsson, 1989).
Depolarization caused by glutamate can lead to the activation of both types of
calcium channels: those that are NMDA-receptor mediated and also voltage sensitive
calcium channels (VSCCs). This in turn can result in an excessive influx of Ca2 into
neurons. In a study published in 1998, in vivo binding of [3H] nimopidine was analyzed in
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PTD animais (Hazeli et ai., 19985). This ligand is an antagonist ofVSCCs that specificaliy
binds to brain regions touched by ischemic insuit which are iikely to deveiop infarction
(Hakim and Hogan, 1991). An increase in specific binding of [3H] nimopidine was seen in
the thalamus while binding in other regions is mostly non-specific. These modifications are
seen before the deveiopment of significant ceil necrosis and subsequent to the loss of the
righting reflex, and this is probably evidence for depolarization and activation of the L-type
of VSCCs in the thalamus. This may indicate the likelihood that an excitotoxic mechanism
is invoived in lesions developed in this neuroanatomical region.
Some observations suggest that the eievation in extraceiluiar glutamate in the
thalamus of acute symptomatic animais can resuit from a Ca2 independant process (Hazeil
and Hakim, 1994). These findings support the hypothesis that the increase in extracellular
glutamate ieveis seen in the thalamic region of symptornatic PTD animais, is due to a
decrease in transmitter glutamate release and a rise in the non-vesicuiar component efflux
from cytopiasmic reservoirs.
1.6.1.2 Selective reduction in astrocytic glutamate transporters
Increases in extracellular glutamate concentrations have been observed, particuiarly
in the thalamus, one of the targeted regions in the PTD model. Despite this, in a recent
study, a decrease in the protein expression ievels of the astrocytic glutamate transporters
GLT-1 and GLAST was shown in vivo (Hazeil et ai., 2001).
It was described a few years ago, that in the mediai thalamus, apoptotic processes
occur prior to the onset of symptoms in this region (Matsushima et al., 1997) or to the
increase in extracellular glutamate leveis (Todd and Butterworth, 1998). Later, the
thalamus develops significant histologicaÏ lesions that are characterized by pannecrosis,
which might 5e indicative of an excitotoxic process. The proposed mechanisms for the
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increase of this neurotransmitter include an elevation of excitation of glutamatergic neurons
possessing NMDA receptors (Langlais and Mair, 1990), a decline in glutamate reuptake
caused by depolarization (Hazeli et al., 199$b), an increase in calcium independent
glutamate release (Hazeli et al.,2001) and dysfunction ofthe glutamate transporters.
In PTD rats at the acute symptomatic stage, a selective increase in extracellular
concentration levels has been shown in the thalamus (Hazell et al., 1993; Langlais and
Zhang, 1993). The fall in GLT-1 and GLAST is flot apparent in pre-symptomatic animais at
the 12th day of treatment, which is concordant with prior observations that confirmed
normal glutamate levels were maintained until the onset of the symptomatic stage (Hazell
et al., 1993) and this supports the hypotheses that states that this decrease is a late event in
this model. The results of these studies indicate that PTD leads to the loss of a critical
astrocytic function, namely the maintenance of homeostasis of extracellular glutamate
levels. This is caused by a malftinction of the transport of this neurotransmitter derived
from the decline of GLT- 1 and GLA$T.
Glutamate transporter activity is also modulated by protein kinase C (PKC) and
cyclic AMP (cAMP). Therefore alterations in phophorylation of the transporter and in
cAMP levels could also lead to the downregulation of GLT-1 and GLAST protein
expression. Another factor that might affect this expression, is the increase in reactive
oxygen species (ROS) and induction of nitric oxyde synthase (NOS), which is an important
souce of free radical production in the thalamus of PTD rats (Langlais et al., 1997;
Calingasan et al., 199$). The increase in production of free radicals can also be a causal
agent ofthe downregulation in glutamate transporters (Gegelashvili and Schousboe, 1997).
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1.7 The Blood Brain Barrier (BBB)
It was suggested several decades ago, that loss ofblood-brain barrier integrity rnight
be a source ofthe brain lesions encountered in WE. Since then, a few studies have focused
on the study of the integrity of this neuroptotective mechanism, particularly in the purely
dietary experimental model and have reported changes in BBB permeability (Warnock and
Burkhalter, 1968; Robertson and Manz, 1971; Manz and Robertson, 1972; Phillips and
Cragg, 1984). Studies done in a more direct manner in the PTD mode!, utilizing
immunohistochemical techniques, have shown disruption of the BBB that allows for
passage of large molecules such as IgG or albumin before and during the onset of the
symptomatic stage (Harata and Iwasaki, 1995; Calingasan et al., 1995a). Furthermore, the
haernorraghic lesions classically seen in the vuinerable regions (Witt, 1985; Vortmeyer and
Colmant, 198$; Calingasan et al., 1995a), rather indicate that loss of integrity of the
capillary vessel walls takes place in PTD. Analogous findings have been reported in
relationto the brains ofWE patients (Schroth et al., 1991).
Pathophysiological processes may produce alterations in BBB integrity in PTD. The
optimal function of the BBB is principally sustained by the cerebral endothelium. The low
permeability characteristic of the BBB, is possible because of the presence in endothelial
ceils of tight junctions and limited vesicular profiles (Reese and Karnovsky, 1967;
Brightman, 1977).
Mechanical opening of endothelial tight junctions are an unusual finding in the
brains of PTD anirnals. When this structure has been observed, tight junction integrity has
been described (Calingasan et al., 1995a; Watanabe, 197$). The augmentation in vesicular
transport across endothelial ceils seen in thiamine deficiency (Manz and Robertson, 1972;
Calingasan et al., 1 995a) has also been observed in other neuropathologies (Hirano et al.,
1994).
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On the other hand, prior studies demonstrating increased transport of high molecular
weight molecules through the BBB have linked this phenornenon to augrnented 333
permeability and also to cerebral oedema (Joô, 1971; Westergaard and Brightman, 1973).
These particular studies suggest that the enhanced immunostaining seen in the cases of IgG
and albumin in the PTD, are evidence of the likely access of detrimental products imported
via the bloodstream into the brain parenchyma. An increase in 333 permeability has been
shown as early as the iO day of pyrithiamine treatment and this trend continues as the
pathology progresses towards the symptomatic stage (Hazeli and Butterworth, 1997).
Aithougli it is possible that the focal lesions seen in this model might be a product
of loss of function of the BBB, this remains sornewhat controversial. Sorne of the structures
that are characteristically targeted in this inodel, such as the inferior colliculus, present a
haemorraghic type lesion, in contrast to the ischemic type lesion seen in the thalamus
(Vortmeyer and Colmant, 1978). Studies examining the brains of WE patients and those of
PTD animais confirm that the thalamus is affected in a different manner than other targeted
neuroanatornical structures in this particular pathology (Torvik, 1985; Matsushima et ai.,
1997; Hazeil et al., 199$a).
Another possibility that has been explored in regards to 333 vulnerability is the one
that suggests that this effect might be caused by a biochernically-mediated process. Recent
studies have shown the presence of amyloid precursor protein (APP) in the targeted regions
(thalamus and inferior colliculus) (Calingasan et al., 1995a, 1996). Studies recently
undertaken, have demonstrated that the 3 arnyloid peptide (Af3), which has consistentiy
been shown to form accumulations in numerous other neurodegenerative pathologies such
as Alzheimer’s (AD), Parkinson’s (PD), Creutzfeld-Jakob (CJD), Huntington’s (HD) and
Down’s syndrome (DS), and that is a fragmentation of APP, significantly increases the
jfluidity of the neuronal membrane as well as contributes to lipid peroxidation (Avdulov et
al., 1997)
These modifications in the membrane’s lipid environment could be influential
towards causing the BBB deterioration seen in PTD. furthermore, Af3 has been shown to
enhance endothelial ceil permeability to albumin (Blanc et al., 1997). This might be a
reason for the easier access of albumin across the brain parenchyma observed in this model
(Harata and Iwasaki, 1995). This effect has been shown to be reversible when antioxidants
were administrated (Blanc et al., 1997). Other studies have also reported that Af3 might be a
possible cause of excitotoxic damage (Koh et al., 1990; Yanker et al., 1990; Mattson et al.,
1992) and can stimulate apoptotic processes (Forloni et al., 1993; Loo et al., 1993). These
resuits indicate that this substance contributes to the increased BBB permeability and the
cell death encountered in PTD.
1.8 Oxidative Stress
The free radical nitric oxide (N0) is known for having neurotoxic effects on the
CNS (ladecola, 1997). N0 causes oxidative damage when it reacts with superoxide anions
Ç02) which leads to the formation of peroxinitrite (0N00) which is a potent oxidative
anion that reacts non-specifically (Merrill et Murphy, 1996). Oxidative damage can cause
lipid peroxidation, DNA fragmentation and enzyme inactivation, including ftee radical
scavengers. There are several sources of superoxide in the CNS and amongst these are
mitochondria, xanthine oxidase, and metabolism of arachidonic acid and also oxidation of
substances such as catecholamines and hemoglobin.
Under normal conditions, superoxide anions derived from various sources are
transformed into hydrogen peroxide (F1202) spontaneously, or catalysed by superoxide
dismutase (SOD). Langlais et al. in 1997 described the presence of reactive oxygen species
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in the thalamus of PTD-treated animals. The possible cause for the increase in free radical
production in the case ofthiamine deficiency is until now flot fully understood but amongst
the probable culprits that have been suggested are increased extracellular glutamate
concentration levels and activation of NMDA receptors, alterations of the BBB, and
activation of microglia and astrocytes. Activated microglia, as was shown in a recent study
(Todd and Butterworth, 1998c), may be responsible for the enhanced production of free
radicals. Reactive microglia are also characteristic of WE, presenting the possibility that
free radical production might be a component of the human pathophysiology of this
disease.
Augmented endothelial transport has been suggested as being a contributing factor
to the dysftmction ofthe BBB seen in PTD (Calingasan et al., 1995a; Harata and Iwasaki.
1995). This indicates that the function of this type of cells might be comprornised in this
case. NO can penetrate the BBB (Au et al., 1985). Endothelial celis and astrocytes are
known to be sources of NO production (Murphy et al., 1990; Moncada et al., 1991). Also
free radicals can enhance permeability of endothelial celis in the brain (Chan et al., 1984).
Therefore this free radical is likely to contribute to BBB disruption in PTD.
Despite a finding that describes a decline in total NOS activity in PTD animals (Rao
et al., 1996) it has been shown in several studies including the present one that there is a
significant increase in the endothelial (eNOS, NOS III) isoform of this enzyme in the
classically targeted regions ofthe brain both by immunohistochemical methods (Calingasan
et al., 1998) or as will be discussed later, by the increases observed in both protein and
mRNA expression.
1.8.1 Nitric Oxide Synthase andNO
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Nitric Oxide (NO) is a small, reactive molecule that is an important bioregulator.
NO is used for a number of cellular signaling functions including blood vessel dilation,
neuronal signal transmission, cytotoxicity against pathogens and turnours, coordination of
heart rhythm and the regulation of celi respiration activity (Murad, 1999). NO is produced
by the heme-containing metalloenzyme, nitric oxide synthase (NOS) (f ig. 1.4). There are
three NOS isoforms, of which two are thought to be constitutive (nNOS and eNOS) in
nature and one which is inducible (iNO$) (Marletta, 1993). (Table 1.0)
Endothelial NOS (eNOS) is mostly membrane bound and formed only in
endothelial celis (furchgott, 1999). Neuronal NOS (nNOS), was identified in the cytosol of
central and peripheral fleurons. NO derived from its constitutive isoforms acts as a
physiological regulator by relaxing vascular smooth muscle or by functioning as a
neurotransmitter. These isoforms produce small amounts of NO for short periods of time in
a Ca2/Calmodulin dependent manner upon stimulation. Endothelial NOS with the
endothelial cell acting as a transducer, releases NO continously in varying arnounts to
regulate blood-vessel tone and by the same means the blood flow and pressure. Large
amounts of NO produced for a prolonged time can cause vasodilation and hypotension. On
the other hand, insufficient NO prodution can be a cause of hypertension.
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-hydroxy-L-arginine L-dtnilline
Fig. 1.4 NO production catalysed by Nitric Oxide Synthase
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Characteristic Endothelial NOS Neuronal NOS Inducible NOS
Dependency on Ca2, Yes Yes No
Calmodulin
Molecular weight in kD 140 155 130
Chromosornal location 7q35-36 12q24.2 17q1 1.12
Producing celis Endothelial Neurons Macrophages,monoc
ytes, astrocytes
Inductors of biosynthesis No No Lipopolysaccharide
(LPS), Inflammatory
cytokines.
Inhibition by L-arginine Yes Yes Yes
analogs.
Inhibition by No No No
glucocorticoids
Table 1. Characteristics of human NOS isoforms
This suggests that NO is involved in the regulation of the vascular system (Ignarro,
L., 1999). Within the CNS, NO is released in response to increases in intracellular Ca2 that
follow stimulation of glutamate receptors. The other function of NO, on which we focus
this study relates to its neurotoxic effects since its excessive release is known to lead to ceil
death processes.
The third isoform of NOS is flot present in resting celis but instead, the ceils must be
induced to express the enzyme, ergo the nomenclature inducible NOS (iNOS). Stimuli
typically includes cytokines and lipopolysaccharide (LPS), and once expressed, the enzyme
A)
‘f-,
generates copious arnounts of NO. A number of cytokines are involved in the production of
iNOS. Among them are IfN-y, IL-1, IL-6, THF-Œ, GM-CSF (granulocyte-macrophage
colony stimulatory factor) and PAF (platelet activating factor) exert the stimulatory effect
whereas the suppression has been observed in the cases of IL-4, IL-8, IL-10, TGF-t3
(transforming growth factor), PDGF (platelet-derived growth factor) and MDF
(macrophage deactivating factor).
NO may react with superoxide to form the highly toxic peroxynitrite anion:
NO + O2 ONOOE
Which in turn may be transformed in an acidic environment to peroxynitrite and
subsequently to the hydroxyl radical:
ONOO+H ONOOH
ONOOH . OH +NO2 NO + H
Independent pathways are involved in the synthesis of reactive oxygen
intermediates (ROI) and reactive nitrogen intermediates (RNI).
The basis of the functional activity of NO is its dual action on some enzymes of
target cells. The small amount of NO released by the constitutive isoforms is sufficient for
the activation of the NO-sensitive enzymes (guanylate cyclase and ADP-ribosyl
transferase) that participate in NO signaling pathways. The larger amonts of NO generated
by iNOS can also activate the NO-sensitive enzymes, but in several celi types the increased
production of NO also exceeds the necessary concentration treshold to inhibit the action of
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certain fe+-containing enzymes, namely aconitase, NADPH-ubiquinone oxidoreductase,
succinate-ubiquinone oxidoreductase, ribonucleotide reductase, NADPH oxidase and
glyceraldehyde-3 -phosphate dehydrogenase.
Activation of soluble guanylate cyclase by NO leads to the synthesis of cGMP,
which in tum, causes the relaxation of vascular smooth muscle ceils, inhibition of platelet
adherence and aggregation, inhibition of neutrophil chemotaxis, and signal transduction in
the central and peripheral nervous systems. NO causes autoribosylation of glyceraldehyde
3-phosphate dehydrogenase, which inactivates this glycolytic enzyme. NO also inhibits
three mitochondrial enzymes: aconitase of the TCA cycle and NADPH ubiquinone
oxidoreductase and succinate —ubiquinone oxidoreductase ofthe electron transport chain.
1.8.1.2 Nitric oxide effects in celi metabolism
NO is known to inhibit cytochrome C oxidase by binding to its heme group and
leading to an upregulated generation of superoxide in the mitochondrial respiratory chain
(Ghafourifar and Richter, 1997). In turn superoxide reacts with NO to yield peroxynitrite
(Ghafourifar et al., 1999). NO or peroxynitrite block respiratory chain complexes I, III, and
TV as well as the activity of cis-aconitase, an enzyme in the TCA cycle, by binding to the
iron-sulfur centers. This inhibition leads to the truncation of the metabolism of acetyl
coenzyme A to carbon dioxide, which is a crucial step in production of nicotinamide
adenine dinucleotide (NADH), which is necessary to fuel oxidative phosphorylation. These
effects severely impair the cell’s ability to conserve and manufacture an adequate reservoir
ofATP.
On the other hand peroxynitrite decomposes into the hydoxyl radical (0H) which is
the most reactive species among those known to cause extensive ceT! and tissue damage in
inflammation. It is widely known to cause lipid peroxydation, DNA mutations and protein
modifications, and has apoptotic and cytotoxic effects on various ceils. The other product
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of the decomposition of peroxynitrite is the NO2 radical that causes nitration of the
tyrosine residues ofproteins.
NO is capable of inducing apoptosis depending on its concentation, flux and the ceil
type on which it is enacting. It activates the transduction pathways that lead to apoptosis.
Pro-apoptotic effects are ofien observed when NO reacts with superoxide to yield the
highly toxic peroxynitrite. Contrary to this, it also can protect ceils against spontaneous or
induced apoptosis. NO inactivates caspases through oxidation and S-nitrosylation of the
active cystein, stimulation of cGMP-dependent protein kinase, modulation of Bcl-2/Bax
farnily, induction of heat shock protein Hsp 70 and interaction with the ceramicle pathway.
The reduction-oxidation state of the ceils appears to be determinant of the ultimate effects
of NO on celi proliferation and survival.
1.8.1.3 Vascular factors in $elective Neuronal Loss in PTD
A recent study by Calingasan et al. (2000) examines the importance and influence
of oxidative stress and vascular changes that are seen in PTD. They approached this by
testing the role of ICAM-1 which is an inducible ecu-surface glycoprotein expressed in
endothelial celis, leukocytes, macrophages and dendritic celis and that of eNOS which is
the subject of the present study and is known to be influenced by inflammatory processes
and therefore may lead to BBB degradation.
It has commonly been suggested that iNOS might be the cuiprit of ceil death and
damage in this particular neuropathology but it has been demonstrated in a prior study
(Calingasan et al., 1998) that it is not necessary to induce the pathology cascade in PTD
since deletion of the iNOS gene did flot mitigate the subsequent and characteristic
neurodegeneration or the induction of heme oxygenase 1 (HO-1), an indicator of oxidative
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stress. Induction of HO- 1, has been correlated to neuronal loss in the thalarnic region in
PTD (Calingasan et al., 1998).
In this study, transgenic mice missing the genes encoding ICAM-1 aiid eNOS were
used, to demonstrate that both are critical factors in the selective neuronal loss ofPTD.
The resuits showed that although eNOS is an effector of basal vasodilation,
excessive endothelium-derived NO is Ïikely to damage neurons.
The resuits obtained in the studies perforrned in the transgenic eNOS-null mice,
suggest that the beneficial effects of vasodilation are less significant than the toxic effects it
lias on PTD. Indeed, the targeted disruption of the eNO$ gene, blunted the deleterious
effects on neurons typical of PTD. This is confirmatory evidence for the hypothesis that
states that NO produced by endothelial cells contributes to TD—induced neurodegeneration.
CHAPTER 2: OBJECTIVES 0F TUE STUDY
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4$
2.1 OBJECTIVES 0F THE STUDY
There is a growing body of evidence that implicates excessive or inappropriate
production of nitric oxide (NO) in disturbances of the the electron transport chain and also
in the disruption ofthe BBB as was mentioned in the introduction.
This smdy seeked to explore temporal gene and protein alterations of the different
NOS isoforms in the PTD model ofneurodegeneration.
mRNA and protein expression of eNOS was determined by RT-PCR and Western
Blot respectively in the medial thalamus, inferior colliculus and frontal cortex of PTD rats
at the presymptomatic and acute symptomatic stages with respect to pair-fed controls
treated following the protocol outlined in the introduction. Appropriately designed
oligonucleotides were used in the RT-PCR experiments and monoclonal antibodies specific
for each NOS isoform were used for the Western Blot protein expression studies. A
confirmatory immunohistochernical study was also carried out, using paraffin embedded
sections of PTD rat brains at the progressing stages of the pathology, using the same
monoclonal antibodies.
Earlier studies in TD have reported increased immunorectivity to NOS in different
ceil types (Calingasan et al., 199$ and 1999), but this is the first study to report consistent
alterations in gene expression in one ofthe NOS isoforms in TD.
The resuits obtained demonstrated a rise in eNOS rnRNA and an increase in eNOS
protein expression in the PTD model. This augmentation of eNOS is concordant with the
resuits reported in prior immunohistochemical studies (Calingasan et ai, 1998) that were
confirrned by immunohistochemistry also in the present study and moreover, provide
further information with respect to the changes in eNO$ expression in the PTD mode!.
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2.2 Incrcased brain endothelial nitric oxide synthase gene expression in
thiamine deficiency: relationship to selective vulnerability.
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Abstract
Thiamine deficiency resuits in selective neuronal cdl death in thalamic structures.
Previous studies provide evidence for a role implicating nitric oxide (NO) in the
pathogenesis of ccli death due to thiamine deficiency. In order to ascertain the origin of
increased NO in the thiamine deficient brain, expression of endothelial nitric oxide
synthase isoform, (eNOS), was meastired in the medial thalamus and in the inferior
colliculus and compared to the frontal cortex (a spared region) of rats in which thiamine
deficiency was induced through a feeding protocol of thiamine-deficient diet concomitant
with daily administration of pyrithiamine, a central thiarnine antagonist. eNOS mRNA and
protein expression were significantly increased as a function of the severity of neurological
impairment and the degree of neuronal cdl loss in the medial thalamus and in the inferior
colliculus. These findings suggest that the vascular endothelium is a major site of NO
production in the brain in thiamine deficiency and that eNOS-derived NO could account for
the selective damage to the thalamic structures as welI as for those seen in the inferior
colliculus that are observed in this particular disorder.
1. Introduction
Oxidative stress resulting from impaired cerebral mitochondrial function is a
hallmark of some acute as well as chronic neurodegenerative disorders such as ischemia,
stroke, Alzheime?s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral
scierosis (review in Fiskum et al., 1999) and Wernicke’s encephalopathy (Butterworth et
al., 1993; Leong and Butterworth, 1996). Interestingly, most of these neurodegenerative
disorders show several common dysfunction including inhibition of the Œ-ketoglutarate
dehydrogenase complex (aKGDH), which is a rate limiting enzyme in the citric acid cycle
and whose function is severely compromised by several factors (review in Gibson et al.,
2000). WernickeTs encephaÏopathy is a unique neurodegenerative disorder caused by a
nutritional/cofactor, namely thiarnine or vitamin B1 deficit. It leads to impaired
mitochondrial oxidative metabolism and consequent neuronal death (Heroux and
Butterworth, 1992), which is ofien reversed by the timely administration of the thiamine
cofactor (Sparacia et al., 1999).
In humans, this disease leads to a syndrome often characterized by
ophthalmoplegia, ataxia, and memory loss. Neuropathological evaluation shows extensive
neuronal celi loss and panecrosis in the thalamic nuclei, mamrnillary bodies, and
cerebellum with relative sparing of cerebral cortical structures (Harper and Butterworth,
1997).
Pyrithiamine induced thiamine deficiency (PTD) in the rat is a well validated
experimental model to study the pathophysiology of human Wemicke’s encephalopathy by
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the nature of its biochemical and region selective histological lesions which mirror those
seen in the human disorder (Troncoso et al., 1981). The earliest metabolic dysfunction
manifested in PTD is the inhibition of ŒKGDH (Butterworth et al., 1986; Butterworth and
Heroux, 1989), an event which resuits in ahered mitochondrial function and is further
responsible foi’ the propagation ofa cascade of abnormalities leading to oxidative stress.
Numerous mechanisms have been proposed to explain the selective neuronal loss
found in TD. They include cerebral energy dysftinction (Aikawa et al., 1984), breakdown
of the blood.-brain barrier (Calingasan et al., 1 995a; Harata and Iwasaki, 1995), altered
glutamate neurotransmission caused by increased extracellular glutamate and its impaired
transporter function (Hazeil et al., 1993, 2001), NMDA receptor-mediated excitotoxicity
(Langlais and Mair, 1990), accumulation of amyloid precursor like protein (Calingasan et
al., 1995b), increased free radical production (Langlais et al., 1997), increased expression
of superoxide dismutase (Todd and Butterworth, 1997), consequent to increased microglial
response (Todd and Butterworth, 1999), induction ofnitric oxide (Calingasan et al., 1998),
and oxidative stress (Langlais et al., 1997; Desjardins and Butterworth, 2003).
As evidence for the increase in oxidative stress, increased nitrotyrosine
immunolabelling of neurons in the classically vuinerable brain regions in the thiarnine
deficiency model have been observed (Calingasan et aI., 1998). On the other hand, when
total nitric oxide synthase (NOS) activities have been measured enzymatically (Rao et al.,
1996), or the densities of NOS-containing neurons have been identified by NADPH
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diaphorase staining (Matsushita et al., 2000), they are significantly downregulated in the
targeted brain regions in the experimental model of TD.
Three distinct isoforms of NOS have been recognized; an inducible NOS (iNOS),
which is usually found in microglia and astrocytes in the brain; a constitutive neuronal
isoforrn (nNOS); and the endothelial isoform (eNOS). The purpose ofthe present study was
to determine the time-course of alterations in expression of the eNOS isoform in brain
structures shown previously to be selectively vuinerable to TD. For this purpose we have
studied the differences in mRNA and protein expression of eNOS in the characteristically
vuinerable regions of the rat brain, using the pyrithiamine-induced thiamine deficiency
model in the rat.
2. Experimental procedures
2.]. Animal surgery
Aduit male Sprague Dawley rats weighing 200-225 g obtained from Charles River
(St. Constant, Quebec, Canada) were used in ah experiments. Rats were housed
individuaily under constant conditions of temperature, humidity and 12 hours light/dark
cycles and had free access to water at ail times. Rats were allowed to adapt to their
environrnent for 3 days prior to the initiation of treatments. At the initiation of the
experiments, anirnals were assigned to either thiamine-deficient or pair-fed control groups.
AlI animal treatment procedures were approved by the Animal Ethics Committee of Saint
Luc Hospital and the University ofMontreal.
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2.2. Thiamine deficiencyprotocol
Rats in the thiamine deficient group (TD) were fed a thiamine-deficient diet (ICN
Nutritional biochemicals, Cleveland, OH, USA) and administered daiiy pyrithiamine
hydrobromide (0.5 mg per kg body wt) intraperitoneally. Control rats were pair-fed to equai
food consumption with the TD rats using the same thiamine-deficient food and were
supplemented with daily i.p. injections ofthiamine (0.1 mg per kg body wt). Afier 12 days
of treatment, rats were randomiy assessed for neurological abnormaiities and seiected to
estabiish a pre-symptomatic stage by careful observation of characteristic symptoms, such
as development of rotating movement and/or tendency towards backward movement
without any seizures or ioss of righting reflex (Hazeil et ai, 1998). Treatments were
continued in the rest of the groups untii rats dispiayed specific behaviors such as ioss of
righting reflex (where the animal is no longer able to right itseif when placed on its back).
This stage was considered as the acute symptomatic stage. Any rats exhibiting spontaneous
seizures were eliminated from the protocols. The animaIs were sacrificed by decapitation.
The brains were promptly removed and flash frozen in isopentane on dry ice and stored at —
80 °C. They were then dissected on ice into three different regions (i.e. frontal cortex,
mediai thalamus and inferior colliculus) according to the rat brain atlas of Paxinos and
Watson (1986).
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2.3. Protein extraction
Media! thalamus, frontal cortex, and inferior colliculus tissue samples were
homogenized at 4°C in 50 mM Tris-HC1 buffer pH 7.4, containing a protease nhibitor
cocktail (Sigma, St.Louis, MO, USA) using a Potter-Elvehjem tissue homogenizer. After
centrifugation of samples at 12,000g for 45 minutes, membranes were separated from
cytosolic fraction, washed in the same buffer and stored at —80°C. Protein concentrations
were estimated based on the method of Lowry et al. (1951) using bovine serum albumin
(BSA) as standard.
2.4. Western blot analysis
Membrane fractions from the media! thalamus, frontal cortex, and inferior colliculus
(10-100 tg protein equivalent) were solubilized in Laemrnli buffer (50 mM Tris-HC1, pH
6.8, 10% glycerol, 2% sodium dodecyl sulfate (SDS), 0.1M dithiothreitol, 0.1%
brornophenol blue) and boiled for 10 minutes. Proteins were resolved on 7.5% denaturing
SDS-polyacrylamide gels and transferred ovemight at 4°C to PVDF membranes.
Membranes were blocked by incubation for two hours at room temperature in Tris buffered
saline containing 0.05% Tween 20 (TBST) and 5% dry milk then incubated for 2 hours
with a monoclonal antibody directed against eNOS (1:1000 dilution; Pharmingen, San
Diego, CA, USA) or 13-actin (1:75,000, Sigma). Membranes were washed several times
with TBST and incubated for 1 hour with an anti-mouse-horseradish peroxidase (HRP)
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conjugated secondaiy antibody (PerkinElmer Life Sciences, Boston, MA, USA). Afler
extensive washing with T3ST, peroxidase activity was detected by enhanced
chernilurninescence using ECL detection system (Amersham, Arlington Heights, IL, USA).
2.5. RNA extraction
Total RNA was extracted from the medial thalamus, frontal cortex, and inferior
colliculus using TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA) according
to the manufacturer’s protocol. Putative contaminating DNA was elirninated by adding 100
U ofRNase-free DNase I per 50 p.g of total RNA at 37°C for 1 h. Purified RNA was then
extracted with phenol, precipitated with ethanol and resuspended in diethylpyrocarbonate
treated water. RNA samples were stored at -70°C until use.
2.6. RT-PCR analysis
Expression of eNOS was investigated by reverse transcription-polymerase chain
reaction (RT-PCR). Total RNA (1 tg) was mixed with 10 mM Tris-HC1, pH 8.3 buffer
containing 1.5 mM MgC12, 50 mM KC1, 0.01% (w/v) BSA, 100 tM dNTPs, primers at Ï
tM each, AMV reverse transcriptase ($OU/ml), Taq DNA polymerase (20 U/ml) and 50
tCi/ml [Œ-32P]dCTP (3000 Ci/mmol), in a total reaction volume of SOpi. Samples were
initially heated at 50°C for 15 min followed by PCR at 95°C for 30 sec, 60°C for 45 sec and
72°C for 1 min. Amplification efficiency conditions were determined afler a kinetic study
to ensure ah experiments were performed within the exponential phase of amplification,
where PCR product remains proportional to initial template concentration (data not shown).
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In ail the experiments, 3-actin was an internai standard to monitor loading variations. f3-
actin and eNO$, were ampiified for 21 and 28 cycles respectively. Afier amplification,
samples were electrophoresed onto 8% polyacrylamide gels, dried and autoradiographed at
—80°C with intensifying screens. Each conesponding hand was excised and Cerenkov
radiation was quantified using a 3-counter. Oligonucleotide primers were designed using
the PRIME program (Genetic Computer Group, Wisconsin) and synthesized by the
Sheldon Biotechnology Center (McGill University, Montreal, Canada) based on the
following gene sequence from GeneBank accession numbers: V01217 (3-actin, Nudel et
al., 1983) with forward and reverse primer sequence 5’-CATCCCCCAAAGTTCTAC-3’
and 5’-CCAAAGCCTTCATACATC-3’ (347 bp), and U53 142 (eNOS, Gnanapandithen et
ai., 1996), 5’-TCAGTGGCTGGTACATGAG-3’ and 5’.ACAGGAAATAGTTGACCATC
TC-3’ (351 bp). The specificity of oligonucleotide primers was verified using BLASTN
(National Center for Biotechnology Information, Bethesda, MD).
2.7. Irnrnunohistochemisty
Rats whose brains were processed for immunohistochemical evaluation were
anaesthetized with pentobarbital (8Omg/kg) and perftised transcardially with 150 ml of
saline followed by 150 ml of neutral-buffered formalin containing 4% formaldehyde, 0.5%
sodium phosphate buffer, 1.5% methanol and 0.02% glutaraldehyde, pH 7.0 (fisher
Scientific, fair Lawn NJ). The brains were then removed and post-fixed ovemight in the
same solution. Paraffin-embedded coronal sections of 6im thickness were cut at the level
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of the frontal cortex and medial thalamus, and mounted on slides coated with Vectabond
Reagent (Vector Laboratories, Burlingame, CA). Siides were deparaffinized by heating at
60°C for 30 minutes followed by xylene, and rehydrated using consecutive baths of ethanol
100%, 95%, 25%, 70%, and distilled water. Endogenous peroxidase was blocked by means
of 1% F1202 in methanol for 30 minutes at room temperature and then washed with PBS.
for eNOS antigen retrieval (AR), the slides were transferred into microwaveable-glass
baths containing 5% urealTris-HC1 buffer, pH 9.5, as formerly described by Shi et al.,
(1996). The baths were heated in a microwave oven twice for 5 minutes (Sanyo Model
EM-8O2TW, operating at 2450 MHz with the highest power setting 600W). When
necessary, more AR buffer was added after the first 5 minutes to compensate for loss due to
boiling over and to avoid drying tissue sections. Afier heating, siides remained in the baths
for an additional 30 minutes before washing in distilled water, followed by P35. The non
specific binding sites were blocked using 10% normal horse serum in 0.5% Triton X
100/PBS for 30 minutes. The slides were incubated overnight with eNOS monoclonal
antibody (1:250, Pharmingen) in a humid chamber at 4°C. Afier washing in PBS, the
sections were then incubated with biotinylated liorse anti-mouse IgGs secondary antibody
(1:100, Vector Laboratories), followed by incubation with ABC reagent (Vector
Laboratories). eNOS immunoreactivity was subsequently detected by incubation with 3-3’-
diaminobenzidine (DAB) containing urea hydrogen peroxide (Sigma). The siides were
counterstained with cresyl violet and mounted for examination. Negative control siides
were treated identically except that the primary antibodies were omitted.
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2.8. Statistical anatysis
Statistical analysis was performed using by two-way analysis of variance (ANOVA)
with Newman Keuls post hoc analysis to establish significance between comparisons. A
probability ofp<O.05 was chosen to establish significance between the groups.
3. Resuits
Afier 11 days of treatment, pyrithiamine-treated animais exhibited changes in
behavior that consisted of rotational and/or backward movements without displaying any
signs of ataxia or opisthotonic episodes, which were consistent with earlier studies (Hazeil
et al., 1998). This was followed on days 13 and 14 by severe ataxia or opisthotonic
episodes lasting for 1$-24 hours, followed by complete loss ofrighting reflex. Time course
study showed no macroscopic brain lesions prior to day 12. Afier day 12, petechial lesions
were observable in the medial thalamus and inferior colliculus on which the present study
focuses. Edema was aiso noticeable at day 12. The consistency of the region-specific
lesions allows for study ofneuropathological changes throughout the chosen time course.
Immunohistochemical staining was performed to investigate eNOS expression in
the frontal cortex and mediai thalamus of symptomatic TD rats. Endothelial ceils of the
medial thalamus from symptomatic rats showed increase eNOS imrnunoreactivity
compared with basal (constitutive) level of expression in the pair-fed group (data not
shown). eNOS immunoreactivity in the mediaÏ thalamus of symptomatic rats was more
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intense and also localized to larger blood vessels when compared to the frontal cortex, a
spared region in thiamine deficiency (Figure 1).
Figure 1
Western blot analysis of eNOS (figure 2) revealed a minor increase in the pre
symptomatic stage when compared to the pair-fed control group and showed a statistically
significant increase in the acute symptomatic stage (2-3 fold, p<O.Ol). There was no
significant variation of eNOS in the non-vuinerable frontal cortex region.
Figure 2
RT-PCR analysis of eNOS mRNA expression in the inferior colliculus and inedial
thalamus revealed, afier normalization to -Actin mRNA, the sarne trend as for eNOS
protein expression, i.e. being significantly increased in the medial thalamus (3 fold,
p<O.001) and inferior colliculus (2 fold, p<O.O5) in the fully symptomatic animals. As
expected, eNOS protein expression in the frontal cortex showed no significant alterations.
Figure 3
o-,
4. Discussion
We found that mRNA and protein expression of the eNOS isoform were increased
in a selective manner in two of the characteristically vuinerable regions in this pathology,
i.e. showing severe neuronal ceil loss (Heroux and Butterworth, 1992), namely the media!
thalamus and inferior colliculus. This increased expression was apparent as of day 12 of
pyrithiamine-induced thiamine deficiency treatment, and these effects took place prior to
the onset of severe neurological symptoms and also of the usual thalarnic lesions found in
this particular animal model (Todd and Butterworth, 1998; Calingasan et al., 1998).
As the pathology advanced, the resulting thiamine deficiency led to ataxia, loss of
righting reflex, and a further increase in eNOS expression in the inferior colliculus and
medial thalamus, two of the typically affected neuroanatomical structures. There was no
significant increase observable in the expression of eNOS in the commonly non-vulnerable
frontal cortex region.
Interestingly, in contrast to this increase in expression of the endothelial isoform,
the expression of the other two isoforms (iNOS and nNOS) presented no significant
changes in either the medial thalamus or the inferior colliculus of the pre-symptomatic or
acute symptomatic PTD- treated animals when the protein or mRNA expression were
measured by Western blot or RT-PCR respectively (data flot shown).
These findings indicate that if NO is implicated in the pathogenesis of neuronal ce!!
death caused by thiamine deficiency, it is likely a product of its increased output from
vascular endothelial celis. Indeed, there is evidence from previous studies that has indicated
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that the vascular endothelium is a major site of free radical production in areas of neuronal
ceil loss in both experimental TD and Wernicke Encephalopathy in humans (Calingasan
and Gibson, 2000; Okeda et al.,1995).
Studies made in a related pathology, experimental cerebral ischemia, tend towards
the conclusion that eNO$ might have a neuroprotective function, which is an effect that
might be caused by its role in modifying presynaptic signals, and this leads to an increase in
GABA release (Kano et al.,1998). Other studies made in cultured celis indicate that NO
derived from eNOS limits apoptotic ceil death (Estevez et al.,199$). The process of
apoptotic celi death has been observed in the thalamic region in experimental TD
(Matsushima et al.,1997), but the extent to which apoptotic ccli death is modulated by the
increase in expression of eNOS in thiamine deficiency has flot yet been explored. On the
other hand, it has been demonstrated that a targeted disruption of the eNOS gene leads to a
reduction in the severity ofthe neuronal damage in a mouse model ofTD (Calingasan et al.,
2000), which points towards the theory that eNOS-derived NO is in fact neurotoxic rather
than neuroprotective.
The increased production of NO by eNOS is a plausible explanation for previous
findings of an increase in nitrotyrosine immunolabelling in experimental TD (Calingasan et
al., 1998), and the increase in NO production could also relate to a recent report of selective
decreases in the expression of cytochrome C oxidase (CCO) in the medial thalamus of TD
animais (Rama Rao et ai., 2000). Increased eNOS expression observed in the present study
showed comparable regionai and temporal profiles to those reported for CCO. These
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findings might be of pathophysiological importance since an inhibitory effect of NO on
CCO expression has been observed in isolated mitochondria and in various neuronal
preparations (Brown, 2001). The decrease in the activity of CCO activity has been
suggested as a possible cause of neuronal celi death in several neurodegenerative disorders
(Kish et al., 1992) and the resuits obtained in the present study indicate that eNOS-derived
NO production, through the production of toxic intermediates such as peroxynitrites, or by
inhibition of CCO and mitochondrial processes, couid be a factor in the pathogenesis of the
selective neuroanatomical lesions seen in syndromes involving TD including Wernicke
encephaiopathy in humans.
Prior studies in TD have reported enhanced irnmunoreactivity to NOS in a variety
of ccli types (Calingasan et al., 1998, 1999). The resuits obtained in the present study, show
an increase in eNOS rnRNA, which precedes an increase in eNOS protein expression in the
acute symptomatic stage. This extends earlier immunohistochernicai studies (Caiingasan et
al., 199$) and demonstrates early, region-selective, increases of eNOS gene expression in
TD.
The finding is important since it was previousiy proposed that NO derived from
iNOS rather than eNOS is a source of the ensuing neurotoxicity in severai
neurodegenerative diseases such as Aizheimer’s disease (Vodovotz et al., 1996) as weli as
in cerebrai ischemia (Endoh et ai., 1994). Increased iNOS expression is plausible in these
particular disorders because under pathologicai conditions (e.g. injury or metabolic insuit),
reactive gliosis couid iead to an inflarnmatory-type of reaction causing induction of iNOS.
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On the other hand, Calingasan et al. (1999) observed that iNOS knockout mice were not
protected from the deleterious effects of TD such as extensive neuronal loss and enhanced
production of free radical species. Rather, the targeted deletion of the eNOS gene reduced
the neurodegeneration and oxidative stress in TD mice. These findings are ail supportive of
the notion that selective eNOS rather than iNOS induction is a key factor in TD leading to
oxidative stress and neuronal celi damage and ioss.
Acknowledgements
This study was supported by a grant from the Canadian Institutes of Health
Research.
67
References
Aikawa, H., Watanabe, I.$., Furuse, T., Iwasaki, Y., $atoyoshi, E., Sumi, T., Moroji, T.,
1984. Low energy Ïevels in thiamine-deficient encephalopathy. J. Neuropathol. Exp.
Neurol. 43, 276-287.
Brown, G.C., 2001. Regulation of mitochondrial respiration by nitric oxide inhibition of
cytochrome C oxidase. Biochim. Biophys. Acta 1504, 46-57.
Butterworth, R.F., Giguere, J.F., Besnard, A.M., 1986. Activities of thiarnine-dependent
enzymes in two experimental models of thiamine-deficiency encephalopathy. 2. alpha
ketoglutarate dehydrogenase. Neurochem. Res. 11, 567-577.
Butterworth, R.F., Heroux, M., 1989. Effect of pyrithiamine treatment and subsequent
thiamine rehabilitation on regional cerebral amino acids and thiamine-dependent enzymes.
J. Neurochem. 52, 1079-1084.
Butterworth, R.F., KriI, J.J., Harper, C.G., 1993. Thiamine-dependent enzyme changes in
the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. Alcohol Clin.
Exp. Res. 17, 1084-108$.
68
Calingasan, N.Y., Baker, H., Sheu, K.F., Gibson, G.E., 1995a. Blood-brain barrier
abnormalities in vuinerable brain regions during thiamine deficiency. Exp. Neurol. 134. 64-
72.
Calingasan, N.Y., Gandy, S.E., Baker, H., Sheu, K.f., Kim, K.S., Wisniewski, H.M.,
Gibson, G.E., 1 995b. Accumulation of amyloid precursor protein-like irnrnunoreactivity in
rat brain in response to thiamine deficiency. Brain Res. 677, 50-60.
Calingasan, N.Y. Park, L.C., Calo, Li., Trffiletti, R.R., Gandy, $.E., Gibson, G.E., 1998.
Induction of nitric oxide synthase and microglial responses precede selective celi death
induced by chronic impairment of oxidative metabolisrn. Am. J. Pathol. 153, 599-610.
Calingasan, N.Y., Chun, W.J., Park, L.C., Uchida. K., Gibson, G.E., 1999. Oxidative stress
is associated with region-specific neuronal death during thiamine deficiency. J.
Neuropathol. Exp. Neurol. 58, 946-958.
Calingasan, N.Y., Gibson, G.E., 2000. Vascular endothelium is a site of free radical
production and inflammation in areas of neuronal loss in thiamine-deficient brain. Ann.
N.Y. Acaci. Sci. 903, 353-356.
69
Calingasan, N.Y., Huang, Pi., Chun, H.S., fabian, A., Gibson, G.E., 2000. Vascular
factors are critical in selective neuronal loss in an animal model of impaired oxidative
metabolisrn. J. Neuropathol. Exp. Neurol. 59, 207-2 17.
Desjardins, P., Butterworth, R.F., 2003. Pathogenesis of selective neuronal loss in
Wernicke-Korsakoff syndrome: roie of oxidative stress. In: Jordan, f., Patel, M.$. (Eds.),
Thiamine: Catalytic Mechanisms and Role in Normal and Disease States. Marcel Dekker
Inc., New York. (In press).
Endoh, M., Maiese, K., Wagner, J., 1994. Expression ofthe inducible form ofnitric oxide
synthase by reactive astrocytes after transient global ischernia. Brain Res. 651, 92-100.
Estevez, A.G., Spear, N., Thompson, J.A., Cornwell, T.L., Radi, R., Barbeito, L., Beckman,
J.S., 1998. Nitric oxide-dependent production of cGMP supports the survival of rat
embryonic motor neurons cultured with brain-derived neurotrophic factor. J. Neurosci. 1$,
3708-3714.
fiskum, G., Murphy, A.N., Beal, M.F., 1999. Mitochondria in neurodegeneration: acute
ischemia and chronic neurodegenerative diseases. J. Cereb. Blood Flow Metab. 19, 351-
369.
70
Gibson, G.E., Park, L.C., Sheu, K.F., Blass, J.P., Calingasan, N.Y., 2000. The alpha
ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 36, 97-112.
Gnanapandithen, K., Chen, Z., Kau, C.L., Gorczynski, R.M., Marsden, P.A., 1996. Cloning
and characterization of murine endothelial constitutive nitric oxide synthase. Biochim.
Biophys. Acta. 1308, 103-106.
Harata, N., Iwasaki, Y., 1995. Evidence for early blood-brain barrier breakdown in
experimental thiamine deficiency in the mouse. Metab. Brain Dis. 10, 159-174.
Harper, C.G., Butterworth, R.F., 1997. Nutritional and Metabolic Disorders. In: Graham,
D.I., Lantos, P.L. (Eds.), Greenfie1ds Neuropathology, Arnold, London, UK, pp. 60 1-655.
Hazeil, A.S., Butterworth, R.f., Haldm, A.M., 1993. Cerebral vulnerability is associated
with selective increase in extracellular glutamate concentration in experimental thiamine
deficiency. J. Neurochem. 61, 1155-1158.
Hazeil, A.S., Hakim, A.M., Senterman, M.K., Hogan, M.J., 199$b. Regional activation of
L-type voltage-sensitive calcium channels in experimentaÏ thiamine deficiency. J. Neurosci.
Res. 52, 742-749.
71
Hazeli, A.S., Rao, K.V., Danbolt, N.C., Pow, D.V., Butterworth, R.F., 2001. Selective
down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST within the
medial thalamus in experimental Wernicke’s encephalopathy. J. Neurochem. 78, 560-56$.
Heroux, M., Butterworth, R.f., 1992. Animal models of Wernicke-Korsakoff Syndrome.
In: Boulton, A.A., Baker, G.B., Butterworth, R.F. (EUs.), Animal Models of Neurological
Disease, Neurornethods, Vol. 22, Humana Press Inc., New-York. pp. 95-131.
Kano, T., Shimizu-Sasamata, M., Huang, P.L., Moskowitz, M.A., Lo, E.H., 1998. Effects
of nitric oxide synthase gene knockout on neurotransmitter release in vivo. Neuroscience
86, 695-699.
Kish, S.J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J.M.,
DiStefano, L.M., Nobrega, J.N., 1992. Brain cytochrome oxidase in Alzheimer’s disease. J.
Neurochem. 59, 776-779.
Langlais, P.J., Mair, R.G., 1990. Protective effects ofthe glutamate antagonist MK-801 on
pyrithiamine-induced lesions and amino acid changes in rat brain. J. Neurosci. 10, 1664-
1674.
72
Langlais, P.J., Anderson, G., Guo, $.X., Bondy, S.C., 1997. Increased cerebral free radical
production during thiamine deficiency. Metab. Brain Dis. 12, 137-143.
Leong, D.K., Butterworth, R.F., 1996. Neuronal celi death in Wernickes encephalopathy:
Metab. Brain Dis. 11, 71-79.
Lowry, O.H., Rosebrough, N.J., Fan, A.L., Randali, R.J., 1951. Protein measurement with
the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
Matsushirna, K., MacManus, J.P., Hakim, A.M., 1997. Apoptosis is restricted to the
thalamus in thiamine-deficient rats. NeuroReport 8, 867-870.
Matsushita, H., Takeuchi, Y., Kosaka, K., Yoshimoto, K., Kawata, M., Sawada, T., 2000.
Changes in nitric oxide synthase-containing neurons in the brain of thiamine-deficient
mice. Acta Histochem. Cytochem. 33, 67-72.
Nudel, U., Zakut, R., Shani, M., Neuman, S., Levy, Z., Yaffe, D., 1983. The nucleotide
sequence ofthe rat cytoplasmic beta-actin gene. Nucleic Acids Res. 11, 1759-1771.
Okeda, R., Taki, K., Ikari, R., Funata, N., 1995. Vascular changes in acute Wernicke’s
encephalopathy. Acta Neuropathol. 89, 420-424.
_7 _,I-J
Paxinos, G., Watson, C., 1986. The rat Brain in Stereotaxic Coordinates. Academic Press,
New-York.
Rama Rao, K.V., Desjardins, P., Butterworth, R.f., 2000. Inhibition of activity and
expression of the cytochrome C oxidase in the thalamus in experimental thiamine
deficiency. J. Neurochem. 74, 573.
Rao, V.L., Mousseau, D.D., Butterworth, R.F., 1996. Nitric oxide synthase activities are
selectively decreased in vuinerable brain regions in thiamine deficiency. Neurosci. Lett.
208, 17-20.
5h, S.R., Cote, R.J., Young, L., Imam, S.A., Taylor, C.R., 1996. Use ofpH 9.5 Tris-HC1
buffer containing 5% urea for antigen retrieval immunohistochemistry. Biotech. T-Iistochem.
71, 190-196.
Sparacia, G., Banco, A., Lagalla, R., 1999. Reversible MRI abnormaÏities in an unusual
pediatric presentation of Wernicke’ s encephalopathy. Pediatr. Radiol. 29, 581-584.
Todd, K.G., Butterworth, R.f., 1997. Evidence that oxidative stress plays a role in neuronal
ceil death due to thiamine deficiency. J. Neurochem. 69, S136A.
74
Todd, K.G., Butterworth, R.F., 1998. Increased neuronal ceil survival afier L-deprenyl
treatrnent in experimental thiamine deficiency. J. Neurosci. Res. 52, 240-246.
Todd, K.G., Butterworth, R.F., 1999. Early microglial response in experimental thiarnine
deficiency: an immunohistochemical analysïs. Glia. 25, 190-198.
Troncoso, J.C., Johnston, M.V., Hess, K.M., Griffin, J.W., Price, D.L., 1981. Model of
Wernicke’ s Encephalopathy. Arch. Neurol. 38, 350-354.
Vodovotz, Y., Lucia, M.S., Flanders, K.C., Chesler, L., Xie, Q.W., Srnith, T.W., Weidner,
J., Murnford, R., Webber, R., Nathan, C., Roberts, A.B., Lippa, C.F., Sporn, M.B., 1996.
Inducible nitric oxide synthase in tangle bearing neurons of patients with Alzheimer’s
disease. J. Exp. Med. 184, 1425-1433.
75
Legends to Figures:
Figure 1. Endothelial nitric oxide (eNOS) immunolabeling in the frontal cortex (A)
and medial thalamus (B) of thiarnine deficient rats at symptornatic stage. Paraffin
embedded sections were probed with eNOS monoclonal antibody. Immunoreactivity was
detected using horseradish peroxidase-coupled anti-mouse IgGs and diarninobenzidine.
Sections were counterstained with cresyl violet. Control sections were incubated with
normal sera instead ofprimary antibody; these showed absence ofimmunostaining.
Figure 2. Western blot analysis of endothelial nitric oxide synthase (eNOS) in the
medial thalamus (A), inferior colliculus (B), and frontal cortex (C) of thiamine deficient
rats. Membrane fraction was prepared from dissected brain regions of thiamine-deficient
rats at presymptomatic (12 days of treatment) and symptomatic stages (loss of righting
reflex) or from pair-fed controls. Proteins were resolved on 8% SDS-polyacrylamide gels,
transferred to PVDf membranes and probed with a monoclonal antibody against eNOS.
Pair-fed controls (PfC); presymptomatic rats (P$); symptomatic rats (SYM). Resuits
shown are representative of duplicate experiments performed with four rats in each group.
Figure 3. Expression of endothelial nitric oxide synthase (eNOS) mRNA in the medial
thalamus (A), inferior colliculus (B), and frontal cortex (C) of thiamine deficient rats. Total
RNA was extracted from dissected brain regions of thiamine-deficient rats at
presymptomatic (12 days of treatment) and symptomatic stages (loss of righting reflex) or
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from pair-.fed controls. B-Actin (347 bp) and eNOS (351 bp) were reverse-transcribed and
amplified by PCR for 21 and 28 cycles respectively. Lane 1: molecular weight standard;
lanes 3-6: pair-fed controls; lanes 7-10 presymptornatic rats; lanes 10-14: symptomatic rats;
lane 2: reverse transcriptase was ornitted from the reaction mixture as negative control.
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Conclusions
3.1 Conclusions
Les expressions de l’ARN messager et de la protéine du NOS endothélial ont
été sélectivement aumentées dans les deux régions caractéristiquement vulnérables
dans la DTP, c’est-a-dire, le thalamus médian et le collicullus inférieur. Les
expressions de L’ARN messager et de la protéine dans le eNOS sont restées sans
changement dans le cortex frontal.Cette augmentation des expressions a été
observée depuis le jour 12 du traitement de déficience en thiamine induite par la
pyrithiamine, et ces changes ont apparut avant la manifestation des symptomes
neurologiques graves (Todd et Butterworth, 199$; Calingasan et al., 199$).
Le processus pathologique induit par le traitement a continué et avec
l’avancement de la déficience en thiamine les animaux ont démontré des symptomes
classiques tels que l’ataxie, la perte du réflexe de redressement et une augmentation
dans l’expression du eNOS dans le colliculus inférieur et dans le thalamus médian
visible au stage pré-symptomatique et augmentant de façon significative lors du
stage symptomatique. L’expression dans la protéine des autres isoformes du
monoxyde d’azote (iNOS et nNOS) resta sans changements consistants quand elle a
été observée par moyen du Western Blot.
Nos résultas semblent indiquer que si le monoxyde d’azote est impliqué dans
le proces de la mort cellulaire neuronale causée par la déficience en thiamine, ceci
est le produit de l’augmentation du NO provenant des cellules vasculaires
endothéliales.
Effectivement, il existe plusieurs études qui démontrent que lendothélium
vasculaire est un site important de production de radicaux libres dans les régions de
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perte neuronale dans la déficience en thiamine et aussi dans l’EW chez l’humain.
(Calingasan et Gibson, 2000; Okeda et al., 1995).
Dans une étude récente, il a été démontré qua l’intérromption spécifique du
gene de eNOS limite les dommages neuronaux dans le modele de la souris utilisé
dans la DT (Calingasan et al., 2000), ce qui indique que le monoxyde d’azote ayant
pour source le eNOS est plutôt neurotoxique et pas neuroprotecteur, ce qui est le
cas dans d’autres pathologies neurodégéneratives telles que l’ischimie.
Ces trouvailles sont importantes car il est généralement pensé que le NO
ayant pour source le iNOS et pas le eNOS est la cause de la neurotoxicité retrouvée
dans plusieurs maladies neurodégénératives telles que la maladie d’Alzheimer
(Vodovotz et al., 1994) et l’ischimie (Endoh et al., 1994). Dans ce maladies, ceci
prends place car dans des conditions pathologiques ( ex. dommages ou insulte
métabolique), il y aurait une prolifération de gliose réactive, ce qui entraîne une
réaction de type inflammatoire qui causerait l’induction du NO par liNOS.
D’après nos résultas et l’evidence montrée par les études mentionnées, ont
peut suggèrer que l’inhibition spécifique du NOS endothélial serait un traitement
potentiel a pousuivre pour réduire la perte neuronale dans les cas avancés
d’encéphalopathie de Wernicke.
3.2 Conclusion
mRNA and protein expression of the eNOS isoform were selectively
increased in the vulnerable brain regions in PTD, namely the medial thalamus and
the inferior colliculus. The rnRNA and protein expression of eNOS remained
unchanged in the frontal cortex. This increased expression of eNOS was observed
starting on day 12 of pyrithiamine-induced thiamine deficiency, before the onset of
severe neurological symptoms. As the thiamine deficiency developed, the animals
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displayed ataxia, loss of righting reflex, and an increase in the expression of eNOS
in the inferior colliculus and medial thalamus that started at the presymptomatic
stage and significantly increased with the onset of the acute symptomatic stage.
The protein expression of the other isoforms of NOS (nNOS and iNOS) did not
display any significant or consistent changes in any region at either the
presymptomatic or acute symptomatic stages when assayed by Western Blotting.
These findings indicate that if NO is implicated in the pathogenesis of neuronal ccli
death caused by thiamine deficiency, it is most likely a product of its increased
output form vascular endothetial cells.Indeed, a growing body of evidence ftom
previous studies suggests that the vascular endothelium is a major site of oxidative
free radical production in areas of neuronal cell loss in both thiamine deficiency and
WE in humans (Calingasan and Gibson, 2000; Okeda et al., 1995).
Studies undertaken in a related pathology, narnely experimental cerebral ischemia,
indicate that eNOS may serve a neuroprotective function, which could be an effect
related to its role in modif4ng presynaptic signal, leading to an increase in GABA
realease (Kano et al., 199$). Studies made in cultured celis indicate that eNOS
derived NO limits apoptotic cell death (Estevez et al., 199$). The process of
apoptotic celi death has been observed in the thalamic region in experimentai
thiamine deficiency (Matsushima et al., 1997), but the extent to which apoptotic celi
death is modulated by the increase in expression of eNOS in thiarnine deficiency
requires further investigation.
It was previously shown that the specific disruption of the eNOS gene lirnits the
extent of the neuronal damage in the murine model of TD (Calingasan et al., 2000),
which indicates that eNOS-derived NO is rather neurotoxic than neuroprotective in
this experimental situation. The rise in production of NO following eNOS induction
could explain the previous findings of an increase in nitrotyrosine immunolabelling
in experimental TD (Calingasan et al., 1998), and the increase in NO production
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could also explain a recent finding that reported selective decreases in the
expression of cytochrome C oxidase (CCO) in the media! thalamus of ID animals t
Rama Rao et al., 2002). In support ofthis, the increased eNOS expression observed
in the present study showed comparable regiona! and temporal profiles to those
reported in the CCO studies. These findings could be of pathophysiological
importance since an inhibitory effect of NO on CCC expression has been observed
in isolated mitochondrion and various neuronal preparations (Brown, 2001). The
decrease in the activity of CCO activity has been suggested as a possible cause of
neuronal celi death in several of the neurodegenerative disorders (Kish et al., 1992)
and the resuits obtained in the present study suggest that eNOS-derived NO
production might, through the production of deleterious intermediates such as
peroxynitrites, or by inhibition of CCC and mitochondrial processes, lead to the
developrnent of the selectivc lesions seen in thiamine dcficiency and, by inference,
in Wernicke encephalopathy in humans.
The earliest pathological event described in this model is the breakdown of
the blood-brain barrier (BBB), which cou!d produce increased NO via eNOS.
Several recent studies have tried to clarify which of the two isoforms might play a
more significant role in the development of the lesions. Calingasan et al. (1999)
demonstrated that in the case of iNOS knockout transgenic mice, these animais
were not protected from the deleterious affects of TD treatment such as extensive
neuronal loss and enhanced production of free radical species. In this same study,
the specific deletion of the eNOS gene limited both the neurodegeneration and
oxidative stress in ID mice. These findings suggest that NO derived from eNOS
and flot iNOS leading to oxidative stress damage, could contribute to the
developrnent of specific lesions in TD pathologies.
The results obtained support the hypothesis that a systemic metaboiic injury
caused by generaiized thiamine deficiency increases NO production and a variety of
other free radical producers in the endothelial cells of the BBB, which ieads to the
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malfunction of this neuroprotective mechanism. The breakdown in the BBB
would then allow the entry of large and deleterious molecules such as iron into the
brain. The entry of these molecules in conjunction with the metabolic alterations
initiates the activation of microglia, which consequently begin an inflammatory
process. Indeed, previous studies (Calingasan et al. 2000) have also demonstrated
that vascular factors are critical in the pathological sequence that terminates in
oxidative stress and death of metabolically impaired neurons in the histologically
vuinerable regions in ID. TD induced ICAM-1 and in the late stages of the
pathology, eNOS are induced in the microvessels of the thalamic region. The use in
these studies of mice devoid of the ICAM-1 and/or eNOS genes led to significant
blunting ofthe neuropathology in this region.
These findings provide further evidence that endothelial ceils are an
important site for inflammatory processes and that they are also significant sources
of free radical production in the sensitive regions of the brain of the PTD animal.
Pharmacological inhibition studies of eNOS would serve to better elucidate the role
ofthis isozyme in the PTD pathology cascade.
In surnrnary, an increase in eNOS production in the vuinerable regions ofthe
brain might be a contributing factor to neuronal ceil death by means of increased
production of NO and other free radical species and thus to oxidative stress
processes.
This increase is likeÏy to be the product of the loss of integrity of the blood
brain barrier in ID and its associated pathologies.
Since these findings indicate that an increase in eNOS production might be
indeed more deleterious than protective in sorne neurodegenerative diseases.
selective inhibition of this isoforrn should be pursued as a potential treatment in
advanced cases of these diseases in the future since it might confer neuronal
protection.
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